800
Views
20
CrossRef citations to date
0
Altmetric
Author's View

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy

&
Article: e27138 | Received 03 Nov 2013, Accepted 08 Nov 2013, Published online: 09 Dec 2013

Figures & data

Figure 1. Combinatorial immunochemotherapy based on immunogenic cell death inducers and oncolytic viruses exerts synergistic anticancer activity. Conventional immunogenic cell death (ICD) inducers such as anthracyclines and UV radiation indirectly provoke an endoplasmic reticulum (ER) stress, leading to the release of damage-associated molecular patterns (DAMPs) within the tumor microenvironment. Oncolytic viruses (OVs) overload the protein translation machinery of malignant cells to directly cause an ER stress and potentially release DAMPs. In addition, the replication of OVs within neoplastic lesions leads to release of foreign viral proteins and nucleic acids that activate immune cells to release cytokines. At least theoretically, the combined administration of ICD inducers and OVs might activate synergistic immunological cascades culminating in improved anticancer immune responses.

Figure 1. Combinatorial immunochemotherapy based on immunogenic cell death inducers and oncolytic viruses exerts synergistic anticancer activity. Conventional immunogenic cell death (ICD) inducers such as anthracyclines and UV radiation indirectly provoke an endoplasmic reticulum (ER) stress, leading to the release of damage-associated molecular patterns (DAMPs) within the tumor microenvironment. Oncolytic viruses (OVs) overload the protein translation machinery of malignant cells to directly cause an ER stress and potentially release DAMPs. In addition, the replication of OVs within neoplastic lesions leads to release of foreign viral proteins and nucleic acids that activate immune cells to release cytokines. At least theoretically, the combined administration of ICD inducers and OVs might activate synergistic immunological cascades culminating in improved anticancer immune responses.